MedPath

University of Zurich

University of Zurich logo
🇨🇭Switzerland
Ownership
Private
Established
1833-04-29
Employees
5K
Market Cap
-
Website
http://www.uzh.ch

Arcturus Therapeutics to Present Phase 2 Data for ARCT-810 mRNA Therapy in Rare Genetic Disorder

Arcturus Therapeutics will host a virtual presentation on June 30, 2025, featuring Phase 2 interim data for ARCT-810, an investigational mRNA therapeutic for ornithine transcarbamylase deficiency.

Phase 1/2 KEYMAKER-U02 Trial: Pembrolizumab Shows Manageable Safety Profile in Stage IIIB-D Melanoma

Neoadjuvant pembrolizumab, alone or combined with vibostolimab or gebasaxturev, demonstrated a manageable safety profile in stage IIIB-D melanoma patients, with 95% experiencing at least one adverse event.

© Copyright 2025. All Rights Reserved by MedPath